Paragon Bioservices Founder Dr. Marco Chacon Elevated to Chairman

 

Baltimore, MD, February 2, 2016/PR Newswire/ – Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the election of the company’s founder, Dr. Marco Chacon, as Chairman of the Company’s Board of Directors, effective January 26, 2016. Dr. Chacon will focus on the strategic growth of the company and development of key corporate initiatives. Peter Buzy, the President of Paragon, will assume responsibility for day‐to‐day operation of the company.

“I am honored and excited to continue the work that Marco started, and together with our talented and dedicated scientists and associates, build our company on the foundation of expertise and customer commitment that has been established,” said Mr. Buzy. “With Dr. Chacon’s leadership and dedication, Paragon has helped develop and manufacture over fifty different biotherapeutics and vaccines and our vision and strategy is to continue to drive this effort to a new level.”

Dr. Chacon remarked, “I am extremely proud of all that has come to fruition at Paragon over the years, and excited about  the  future  of  the  company.  Responsibility  to  our  clients,  a  passion  for  science  and  our collective  need  to  contribute to better public health—that’s what keeps us motivated and excited about the work that we perform.” Dr.  Chacon  noted,  “We  are  driven  by  our  commitment  to  provide  exceptional  quality,  scientific  excellence  and  superior customer service, and I look forward to guiding Paragon toward realizing its full potential.”

About Paragon Bioservices, Inc.
Paragon  Bioservices  is  a  private‐equity  backed  contract  development  and  manufacturing  organization  (CDMO)  whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification  of  monoclonal  antibodies,  recombinant  proteins,  viral  vectors  and  vaccines. The  company  provides  research services, process development and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.

Media Contact
Kevin Sly, SVP Marketing & Commercial Strategy
PH (410) 975‐4053′

Printable version

Have questions? Ready to get started?

Fill out the form below and we’ll be in touch ASAP.

* These fields are required.

Who we are. How we work.

Learn More About Paragon

Want info on specific expertise?

Request a Brochure

Have a question? Let us help.

Contact Us